ClinicalTrials.gg
RecruitingNCT07731126TRANSCAREUpdated Jul 28, 2026

New Care Pathways for Supporting TRANSitional CARE From Hospital to Home Using AI and Personalized Digital Assistance

An interventional study of TRANSCARE Digital Remote Monitoring Ecosystem in Transitional Care, Remote Patient Monitoring (RPM) and Geriatric Multimorbidity, sponsored by Istituto Nazionale di Ricovero e Cura per Anziani. Recruiting at 3 sites in 3 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Istituto Nazionale di Ricovero e Cura per Anziani · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2025, registered Jul 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The objective of the TRANSCARE study is to evaluate the use of a digital remote monitoring system to reduce the risk of 30-day readmission in multimorbid elderly patients. The pilot study is multicenter, and the trial will be conducted across 3 sites: Italy, Romania, and Norway. The overall goal of the TRANSCARE project is to create a digital monitoring ecosystem capable of identifying and preventing the risk of readmission. Two hundred and ten older adults aged over 65, who meet the inclusion and exclusion criteria, will be enrolled in the study. They will be randomized into two groups and allocated to an intervention group or a control group.

02

Conditions studied

  • Transitional Care
  • Remote Patient Monitoring (RPM)
  • Geriatric Multimorbidity

Keywords

  • Digital Health Ecosystem
  • Remote Patient Monitoring (RPM)
  • Multimorbidity
  • 30-Day Hospital Readmission
  • Self-Management Empowerment
  • Older Adults / Geriatric Care
  • Machine Learning Predictive Modeling
  • eHealth Literacy
  • Multicenter Pilot Study
03

In context

Lead sponsor

Istituto Nazionale di Ricovero e Cura per Anziani is the lead sponsor of 42 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to stand and walk even with support;
  • (MMSE) ≥ 18;
  • Clinical Frailty Scale (CFS) score 2-7;

Exclusion criteria

Exclusion Criteria:

  • Allergy to nichel components;
  • Concomitant participation in other studies;
  • Severe dementia condition
  • Mild to moderate dementia condition in the absence of the caregiver
  • Terminal chronic renal failure with the need for dialysis
  • Inability or unwillingness to sign written ;
  • Pacemaker or implantable cardioverter defibrillator;
  • cancer or therapy;
  • Significant visual or hearing impairment;
  • Severe systemic diseases with \< 6 year;
  • Move to nursing home after discharge
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    TRANSCARE Ecosystem Group

    Participants in this arm will receive the TRANSCARE digital remote monitoring ecosystem upon hospital discharge for a duration of 90 days. This includes a suite of home medical monitoring devices (for measuring physiological vital signs) and a wearable activity tracking device connected to a central digital platform. Participants will use these tools for daily health self-monitoring to enable early risk detection and promote self-management capabilities. In addition to the technological intervention, participants will receive standard post-discharge care.

    Other: TRANSCARE Digital Remote Monitoring Ecosystem

  • No intervention
    Usual Care Group

    Participants in this arm will receive standard post-discharge care (usual care) provided by the national healthcare system without the TRANSCARE digital monitoring tools or wearable devices.

Interventions

  • OtherTRANSCARE Digital Remote Monitoring Ecosystem

    A digital remote monitoring suite comprising connected home medical devices for physiological parameter measurement, a wearable activity tracker, and an integrated telemonitoring software platform designed for patient self-management and clinical risk detection.

06

What researchers measure

Primary outcomes

  1. 30-Day Re-hospitalization Rate

    Percentage of participants re-admitted to the hospital for any all-cause unplanned readmission within 30 days following discharge.

    Time frame: 30 days post-discharge

Secondary outcomes

  1. Re-hospitalization Rate at 60 days

    Percentage of participants with all-cause unplanned hospital readmissions evaluated at 60 days post-discharge.

    Time frame: 60 days post-discharge

  2. Re-hospitalization Rate at 90 Days

    Percentage of participants with all-cause unplanned hospital readmissions evaluated at 90 days post-discharge

    Time frame: 90 days post-discharge

  3. Change in Physical Performance

    Assessment of physical performance using the Short Physical Performance Battery (SPPB) score (range 0-12, where higher scores indicate better physical function).

    Time frame: Baseline, 30 days, 60 days, and 90 days post-discharge.

  4. Platform Usability

    Usability of the digital monitoring ecosystem evaluated using the System Usability Scale (SUS) (score 0-100)

    Time frame: 30 days, 60 days, and 90 days post-discharge

  5. Psychosocial Impact of Technology

    The perceived impact evaluated through the Psychosocial Impact of Assistive Devices Scale (PIADS)

    Time frame: 30 days, 60 days, and 90 days post-discharge

  6. Change in Digital Health Literacy

    Evaluation of digital health literacy skills measured using the eHealth Literacy Scale (eHEALS) (score 8-40, higher scores indicate higher perceived eHealth literacy).

    Time frame: Baseline and 90 days post-discharge

07

Study locations

3 of 3 sites recruiting
  • IRCCS INRCA Hospital
    Ancona, 60127, Italy
    Recruiting
    • Antonio Cherubini, Prof. MD · Contacta.cherubini@inrca.it · +390718003537
    • Antonio Cherubini, Prof. Dr. · Principal investigator
  • Farsund Kommune
    Farsund, Norway
    Recruiting
  • Institutul Inimii "Niculae Stăncioiu"
    Cluj-Napoca, Romania
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartActual
Dec 12, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07731126
Lead sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Collaborators
Technical University of Cluj-Napoca, Romania, INSTITUTUL INIMII "NICOLAE STANCIOIU" CLUJ-NAPOCA, Romania, Tellu AS, Norway, Farsund Kommune, Norway, Karde AS, Norway
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Dec 12, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Anna Rita Bonfigli, PhD
Contact
a.bonfigli@inrca.it
0718003719
Ionut Anghel, Prof. Dr.
study chair · Technical University of Cluj-Napoca, Romania
Roberta Bevilacqua, Ph.D.
principal investigator · IRCCS INRCA, Ancona, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion